Xspray Pharma
Develops improved cancer drugs (PKIs) using a patented amorphous formulation technology.
XSPRAY | ST
Overview
Corporate Details
- ISIN(s):
- SE0009973563 (+3 more)
- LEI:
- 549300NGRQCNZ3X4L157
- Country:
- Sweden
- Address:
- Scheeles väg 2, 171 65 Solna
- Website:
- https://xspraypharma.com/
- Sector:
- Manufacturing
Description
Xspray Pharma is a pharmaceutical company that utilizes its patented technology platform to develop improved versions of marketed drugs, primarily focusing on Protein Kinase Inhibitors (PKIs) for cancer treatment. The company's core innovation lies in its ability to create stable, amorphous (non-crystalline) formulations of active pharmaceutical ingredients. This unique approach enables the development of product candidates that can bypass the secondary patents of original crystalline drugs, facilitating market entry upon the expiration of the primary substance patent. Xspray Pharma's products are designed to offer clinical benefits for patients compared to the original branded drugs and their subsequent generic equivalents.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-01-29 15:45 |
Antal aktier och röster i Xspray Pharma
|
Swedish | 42.9 KB | ||
| 2021-01-29 15:45 |
Number of shares and votes in Xspray Pharma
|
English | 43.1 KB | ||
| 2021-01-26 13:00 |
Warrant holders exercise all warrants within the framework of the incentive pro…
|
English | 45.1 KB | ||
| 2021-01-26 13:00 |
Optionsinnehavare utnyttjar samtliga teckningsoptioner inom ramen för incitamen…
|
Swedish | 44.8 KB | ||
| 2021-01-22 12:55 |
Xspray Pharmas study with modified formulation of HyNap-Dasa has now started
|
English | 44.1 KB | ||
| 2021-01-22 12:55 |
Xspray Pharmas studie med modifierad formulering av HyNap-Dasa har nu startats
|
Swedish | 44.2 KB | ||
| 2021-01-14 12:10 |
Xspray Pharma announces results from additional bioequivalence study and provid…
|
English | 48.7 KB | ||
| 2021-01-14 12:10 |
Xspray Pharma meddelar resultat från extra bioekvivalensstudie och lämnar uppda…
|
Swedish | 48.5 KB | ||
| 2020-12-29 18:05 |
Xspray Pharma’s HyNap-Nilo receives FDA Orphan Drug Designation for the treatme…
|
English | 46.7 KB | ||
| 2020-12-29 18:05 |
Xspray Pharmas HyNap-Nilo erhåller särläkemedelsstatus från FDA för behandling …
|
Swedish | 47.0 KB | ||
| 2020-12-11 13:10 |
Xspray Pharma har beslutat att invänta resultaten från två pågående kliniska st…
|
Swedish | 45.9 KB | ||
| 2020-12-11 13:10 |
Xspray Pharma has decided to await the result of two ongoing clinical studies b…
|
English | 45.7 KB | ||
| 2020-11-20 07:45 | Swedish | 676.8 KB | |||
| 2020-11-20 07:45 | English | 641.2 KB | |||
| 2020-10-30 14:30 |
Antal aktier och röster i Xspray
|
Swedish | 42.7 KB |
Automate Your Workflow. Get a real-time feed of all Xspray Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xspray Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xspray Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-10 | Anders Ekblom | Other | Buy | 168,000 | 4,998,000.00 SEK |
| 2024-06-04 | Ribbskottet AB Anders Bladh | Other | Buy | 1,958 | 145,655.62 SEK |
| 2024-06-03 | Anders Bladh, Ribbskottet | Other | Buy | 3,042 | 225,077.58 SEK |
| 2024-05-29 | Per Andersson | Other | Buy | 51,749 | 489,545.54 SEK |
| 2024-05-27 | Per Andersson | Other | Sell | 9,950 | 687,545.00 SEK |
| 2024-05-16 | Anders Bladh | Other | Buy | 10,000 | 503,500.00 SEK |
| 2024-05-02 | Maris Hartmanis | Other | Other | 2,385 | 95,400.00 SEK |
| 2024-05-02 | Christine Lind | Other | Other | 666 | 26,640.00 SEK |
| 2024-05-02 | Anders Ekblom | Other | Other | 500 | 20,000.00 SEK |
| 2024-03-05 | Robert Molander | Other | Buy | 5,000 | 20,000.00 USD |
Peer Companies
